SCHEMBL16369409

SCHEMBL16369409

CC(C)C1=CCc2cnccc21

nearest known ligand 0.35

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 1/20 0.35
RPS6KA3 P51812 1/20 0.34
MAOA P21397 1/20 0.33
MAOB P27338 1/20 0.33
CHRNB2 P17787 1/20 0.32
CHRNA4 P43681 1/20 0.32
CDC25B P30305 1/20 0.32
AAK1 Q2M2I8 2/20 0.32
TP53 P04637 1/20 0.30
CYP3A4 P08684 1/20 0.30
MAPT P10636 1/20 0.30
TSHR P16473 1/20 0.30
MAPK1 P28482 1/20 0.30
CASP1 P29466 1/20 0.30
BLM P54132 1/20 0.30
CASP7 P55210 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13496206 0.76 SIGMAR1 (0.40) SIGMAR1RPS6KA3MAOAMAOBCHRNB2
SCHEMBL30084467 0.72 PTPN1 (0.39) MAOAMAOBCDC25B
SCHEMBL2970358 0.72 SIGMAR1 (0.40) SIGMAR1RPS6KA3MAOAMAOBCHRNB2
SCHEMBL28332411 0.71 RPS6KA3 (0.39) SIGMAR1RPS6KA3MAOAMAOBCHRNB2
SCHEMBL14030317 0.70 SIGMAR1 (0.35) SIGMAR1CHRNB2CHRNA4AAK1TP53
SCHEMBL14048224 0.70 MPO (0.36) SIGMAR1CHRNB2CHRNA4AAK1
SCHEMBL6408659 0.69 RPS6KA3 (0.44) RPS6KA3MAOAMAOBCDC25BTP53
SCHEMBL13496207 0.67 SIGMAR1 (0.43) SIGMAR1RPS6KA3MAOAMAOBCHRNB2
SCHEMBL16369419 0.67 SIGMAR1 (0.35) SIGMAR1RPS6KA3MAOAMAOBCHRNB2
SCHEMBL16369408 0.67 GABRG2 (0.31)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180194746-A1 Compounds For the Treatment of HIV GILEAD SCIENCES, INC. 2018-07-12 US disclosed
US-9944619-B2 Compounds for the treatment of HIV GILEAD SCIENCES, INC. (US) 2018-04-17 US disclosed
US-20170369486-A1 GEMINAL SUBSTITUTED QUINUCLIDINE AMIDE COMPOUNDS AS AGONISTS OF ALPHA-7 NICOTONIC ACETYLCHOLINE RECEPTORS AXOVANT SCIENCES GMBH (CH) 2017-12-28 US disclosed
US-20170137405-A1 COMPOUNDS FOR THE TREATMENT OF HIV GILEAD SCIENCES, INC. 2017-05-18 US disclosed
US-9540343-B2 Compounds for the treatment of HIV GILEAD SCIENCES, INC. (US) 2017-01-10 US disclosed
US-8921361-B2 Triazine, pyrimidine and pyridine analogs and their use as therapeutic agents and diagnostic probes UNIVERSITY OF BASEL (CH) 2014-12-30 US disclosed
US-20140142085-A1 COMPOUNDS FOR THE TREATMENT OF HIV GILEAD SCIENCES, INC. (US) 2014-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180194746-A1 Compounds For the Treatment of HIV CCR5, NPC1, FURIN SIGMAR1 3207/4885RPS6KA3 1040/4885MAOA 2538/4885
US-20170369486-A1 GEMINAL SUBSTITUTED QUINUCLIDINE AMIDE COMPOUNDS AS AGONISTS OF ALPHA-7 NICOTONIC ACETYLCHOLINE RECEPTORS CHRNA7, CHRNA6, CHRNA5 SIGMAR1 823/4885RPS6KA3 3464/4885MAOA 2098/4885
US-20170137405-A1 COMPOUNDS FOR THE TREATMENT OF HIV CCR5, NPC1, FURIN SIGMAR1 3207/4885RPS6KA3 1040/4885MAOA 2538/4885
US-20140142085-A1 COMPOUNDS FOR THE TREATMENT OF HIV CCR5, NPC1, FURIN SIGMAR1 3207/4885RPS6KA3 1040/4885MAOA 2538/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.